Angiogenesis is obligatory in the enhancement of progression (growth, invasion and metastasis) of solid tumours (Folkman, 1995). New vessels promote growth by conveying oxygen and nutrients and removing catabolites, whereas endothelial cells secrete growth factors for tumour cells (Hamada et al, 1992; Folkman, 1995). Endothelial cells also secrete a variety of matrix-degrading proteinases which facilitate invasion (Mignatti and Rifkin, 1993). Lastly, an expanding endothelial surface increases opportunities for tumour cells to enter the circulation and metastasize (Aznavoorian et al, 1993).

Tumour cells may not be the only source of angiogenic factors within a tumour. Host inflammatory cells, including fibroblasts, macrophages and mast cells (MCs), which are recruited and activated by tumour cells via paracrine mechanisms act synergistically with these cells by secreting the same or other factors (Polverini, 1996). MCs play a decisive role in the synergism (Norrby and Whooley, 1993). Also, experimentally induced tumours display MC accumulation close to the tumour cells before the onset of angiogenesis (Kessler et al, 1976), and those induced in MC-deficient mice display both reduced angiogenesis and ability to metastasize (Aznavoorian et al, 1993).

Tumour cells may not be the only source of angiogenic factors within a tumour. Host inflammatory cells, including fibroblasts, macrophages and mast cells (MCs), which are recruited and activated by tumour cells via paracrine mechanisms act synergistically with these cells by secreting the same or other factors (Polverini, 1996). MCs play a decisive role in the synergism (Norrby and Whooley, 1993). Also, experimentally induced tumours display MC accumulation close to the tumour cells before the onset of angiogenesis (Kessler et al, 1976), and those induced in MC-deficient mice display both reduced angiogenesis and ability to metastasize (Aznavoorian et al, 1993).

Knowledge on these relations in haematological tumours is circumstantial. Angiogenesis is correlated with tumour growth (S-phase fraction) in monoclonal gammopathies (Vacca et al, 1994), and with progression stages in B-cell non-Hodgkin’s lymphomas (Ribatti et al, 1998) and in mycosis fungoides (Vacca et al, 1997).

This paper presents the results of an investigation on angiogenesis and MC counts in the bone marrow of patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) grouped according to a pathway of progression.

**MATERIALS AND METHODS**

**Patients**

A total of 80 Caucasian patients who fulfilled the South West Oncology Group diagnostic criteria for MM and MGUS (Durie, 1991) were studied (Table 1). Myeloma patients were defined as active or non-active, according to clinical performance and response to treatment.

**Table 1** Patient clinical and immunological data

| Total no. | 80 |
|----------|----|
| Multiple myeloma | 58 |
| Active | 24 |
| Average age (median, range) | 66 years (66.5, 42–87) |
| Men/women | 15/9 |
| M-component IgG/IgA/IgD/IgM | 16/6/1/1 |
| Diagnosis | 10 |
| Stage I/II/III; A/B | 1/2/7; 8/4 |
| Relapse | 8 |
| Progression | 6 |
| Non-active | 34 |
| Average age (median, range) | 66 years (68, 45–80) |
| Men/women | 20/14 |
| M-component IgG/IgA/IgD/IgM | 22/8/4 |
| Response | 20 |
| Plateau | 14 |
| Monoclonal gammopathy of undetermined significance | 22 |
| Average age (median, range) | 67 years (63.8, 45–86) |
| Men/women | 12/10 |
| M-component IgG/IgA/IgM | 18/2/2 |

*According to Durie and Salmon. +Relapse defined as M-component increase >50% from the lowest value, or clinical and bone marrow relapse when the M-component did not reflect tumour load and disease activity. +Plateau phase defined as post-treatment M-component decrease >50%, and lasting for at least 6 months without treatment.
M-component level (Durie, 1991). Active patients were those: (a) at diagnosis, with symptomatic disease and an increase in the M-component level in the 3 months before analysis; (b) at relapse; (c) with unresponsive and rapidly progressive disease (leukaemic progression), characterized by severe bone pain, hypercalcaemia and pancytopenia. Non-active patients were those in: (a) post-treatment complete/objective response; (b) the off-treatment plateau phase. MGUS, non-active-MM and active MM constitute a progression pathway because: (i) the clinical evolution from one step to the next is typical; (ii) the plasma cell S-phase fraction and tumour mass rise significantly in the transition from one step to the next (Durie, 1991).

The study was approved by the local ethics committee and all patients gave their informed consent.

### Measurement of bone marrow angiogenesis

All blood vessels were displayed in 6-μm sections of 4% paraformaldehyde-fixed paraffin-embedded biopsies by staining endothelial cells with the anti-factor VIII murine monoclonal antibody M616 (IgG1; Dako, Glostrup, Denmark) and a three-layer biotin–avidin–peroxidase system described previously (Vacca et al, 1994). The very few megakaryocytes also stained by factor VIII

|                  | MGUS (n = 22) | Non-active MM (n = 34) | Active MM (n = 24) |
|------------------|--------------|------------------------|-------------------|
| Microvessel area (μm²) | 1.1 ± 0.5 (0.9; 0.2–2.5) | 1.2 ± 0.6 (1.3; 0.2–2.2) | 5.7 ± 3* (5.2; 1.2–12.8) |
| Number of mast cells | 1.3 ± 1* (1; 0–3) | 1.6 ± 1.2 (1.5; 0–4) | 4.8 ± 2* (5; 1–8) |

Results are expressed as means ± 1 standard deviation (median; range) in 250× microscopic fields (125 μm²). The cellular area in MGUS, non-active and active MM was 42.1 ± 8.8 μm², 46.6 ± 11.2 μm² and 52.4 ± 9.6 μm². *P < 0.01 compared with non-active MM and MGUS

Figure 1. Adjacent sections of bone marrow biopsies stained with factor VIII for microvessels (A, C, E) and with toluidine blue for mast cells (B, D, F) from patients with: (A) and (B) active MM (relapse); (C) and (D) non-active MM (plateau); and (E) and (F) MGUS. Note the higher density of microvessels and mast cells (some are arrowheaded) in the active MM patient. Bar = 10 μm
Angiogenesis was measured as microvessel area without knowledge of final diagnosis. Briefly, six to eight 250× fields covering the whole of each of two sections per biopsy were examined with a superimposed 484-point square reticulum (125 mm²) to identify microvessels (capillaries and small venules) as endothelial cells either single or clustered in nests or tubes, and clearly separated from one another, and either without or with a lumen (not exceeding 10 μm). A planimetric point count method (Elias and Hyde, 1983) with slight modifications for the computed image analysis (Leica Quantimet 500, Wetzlar, Germany) was applied to measure the microvessel area within the cellular area (reticulum area minus connective tissue, fat, bone lamellae, necrosis and haemorrhage areas) (Vacca et al, 1994). Values are expressed as means ± 1 standard deviation (s.d.) per group of patients.

**MC counts**

MCs were highlighted in two sections adjacent to that stained for microvessels with 0.5% aqueous solution of toluidine blue (Merk, Darmstadt, Germany). Cells were counted in six to eight 250× fields inside the reticulum and calculated as means ± 1 s.d. for each group of patients.

**Electron microscopy**

Small pieces (approximately 1 mm³) of tissue were fixed in 3% glutaraldehyde in 0.1 M phosphate-buffered saline (PBS) for 3 h,
washed in the same buffer for 12 h, post-fixed in 1% osmium tetroxide, dehydrated in graded ethanol and embedded in Epon 812. Ultrathin sections were cut with a diamond knife on a LKB V ultratome, stained with uranyl acetate followed by lead citrate, and examined in a 9A Zeiss electron microscope.

**Statistics**

The significance of changes in the microvessel area and MC counts in the groups was determined with the parametric (Fisher’s test) and non-parametric (Kruskal–Wallis test) analysis of variance, followed by Duncan (τ), Bonferroni (τ), and Wilcoxon tests to compare groups two by two. Correlations between microvessel area and MC counts in the groups were assessed with the Pearson’s (r) coefficient and simple regression analysis. Data were computed with the Statistical Analysis Software (SAS, SAS Institute, Cary, NC, USA).

**RESULTS**

Table 2 shows the microvessel area normalized to the total cellular area and the MC counts on bone marrow adjacent sections of patients with active MM, non-active MM and MGUS. The area was significantly larger in patients with active MM than in those with non-active MM and with MGUS, between which variations were negligible. In parallel, the MC counts were significantly higher in active MM than in the other groups. The differences in microvessels and MC are also shown in Figure 1. The within-group comparison showed that both parameters were always significantly correlated (Figure 2). At the ultrastructural level, typical MCs with cytoplasmic matrix filled by numerous electron dense secretory granules (Figure 3A), and MCs with semilunar aspect of granules (Figure 3B) were recognizable. The latter imply slow, chronic release of mediators in response to a moderate, progressive, degranulatory stimulus (Kops et al, 1984; Ribatti et al, 1988).

**DISCUSSION**

In the current study, we showed that bone marrow angiogenesis (evaluated as microvessel area) and MC counts were highly correlated in patients with non-active and active MM and MGUS, and that both parameters increased simultaneously in active MM. As the progression from in situ to invasive and metastatic solid tumours is accompanied and facilitated by the local recruitment and activation of inflammatory cells, including MCs, it may be induced by tumour plasma cells via secretion of angiogenic factors, such as IL-6 and IL-8 (Motro et al, 1990; Norrby, 1996), TNF-α (Beil et al, 1994), granulocyte–macrophage colony-stimulating factor (GM-CSF) (Bussolino et al, 1991), TGF-β (Roberts et al, 1986), FGF-2 (Qu et al, 1995) and VEGF-A (Grutzkan et al, 1996), which may contribute to angiogenesis in active MM.

As concerns the ultrastructural features of MCs, the semilunar, or partial degranulating, aspect of their secretory granules, unlike IgE-mediated massive degranulation which occurs during the immediate hypersensitivity reactions, is typical of a slow degranulation, taking place in delayed hypersensitivity reactions and in chronic inflammatory processes (Kops et al, 1984; Ribatti et al, 1988). In tumours, such as MM, the semilunar aspect of MC secretory granules might correspond to a slow but progressive release of angiogenic factors, in consequence of a chronic and progressive stimulation of MC degranulation.

Tentatively, our data suggest that an increasing number of MCs may be recruited and activated by more malignant plasma cells in active MM, and that angiogenesis in this disease phase may be mediated, at least in part, by angiogenic factors contained in their secretory granules.

**ACKNOWLEDGEMENTS**

This work was supported in part by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy) to FD and from Ministero dell’Università e della Ricerca Scientifica e Tecnologica (MURST, Funds 60% and exc 40%, Rome, Italy) to DR and AV.

**REFERENCES**

Alessandri G, Raja KS and Gullino PM (1984) Characterization of a chemotacticoaggregating factor from endothelium induced by angiogenic effectors. *Cancer Res* 44: 1579–1584

Aznavoorian S, Murphy AN, Steller-Stevenson WG and Liotta LA (1993) Molecular aspects of tumor cell invasion and metastasis. *Cancer* 71: 1368–1383

Beil WJ, Login GR, Galli SJ and Dvorak AM (1994) Ultrastructural immunogold localization of tumor necrosis factor-α on the cytoplasmic granules of rat peritoneal mast cells with rapid microwave fixation. *J Allergy Clin Immunol* 94: 531–536

Blair RJ, Mengh H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG and Gruber BL (1997) Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. *J Clin Invest* 99: 2691–2700
Angiogenesis and mast cells in human multiple myeloma

Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O, Bosia A, Marchisio PC and Mantovani A (1991) *In vitro* and *in vivo* activation of endothelial cells by colony stimulating factors. *J Clin Invest* 87: 986–995

Castellot JJ, Karnovsky MJ and Spiegelman BM (1982) Differentiation-dependent stimulation of neovascularization and endothelial cell chemotaxis by T3 adipocytes. *Proc Natl Acad Sci USA* 79: 5597–5601

Cozzolino F, Torcia M, Aldinucci D, Rubatelli A, Miliani A, Shaw AR, Lansdorp PM and DN Guglielmo R (1989) Production of interleukin-1 by bone marrow myeloma cells. *Blood* 74: 380–387

Dethlefsen SM, Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O, Bosia A, Marchisio PC and Mantovani A (1993) Separable growth and migration stimulation of neovascularization and endothelial cell chemotaxis by 3T3 adipocytes. *Proc Natl Acad Sci USA* 79: 5597–5601

Kessler DA, Langer RS, Pless NA and Folkman J (1976) Mast cells and tumor metastasis. *Invasion Metastasis* 14: 395–408

Durie BGM and Salmon SE (1977) Multiple myeloma, macroglobulinemia and their relation to angioneogenesis. *Blood* 49: 196–205

Destito RJ, Cavanagh PG and Lotan R (1992) Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. *Invasion Metastasis* 14: 395–408

Dethlefsen SM, Matsuura N and Zetter BR (1994) Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. *Invasion Metastasis* 14: 395–408

Durie BGM (1991) Staging and kinetics of multiple myeloma. In *Neoplastic Disorders of the Blood*. Wierny PH, Canellios GP, Kyle RA and Schiffer CA (eds.), pp. 439–451, Churchill Livingstone: New York

Durie BGM and Salmon SE (1977) Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In Recent Advances in Haematology. Hoggbrand AV, Blain MC and Hirsh H (eds.), pp. 234–261, Churchill Livingstone: New York

Elias H and Hyde DM (1983) Stereological measurements of isotropic structures. In *A Guide to Practical Stereology*. Elias H and Hyde DM (eds.), pp. 25–44, Karger: Basel

Folkman J (1995) Clinical applications of research on angiogenesis. *Blood* 85: 1838–1844

Gruber BL, Marchese MJ and Kew R (1995) Angiogenic factors stimulate mast cell activation and a high-molecular weight fraction stimulates angiogenesis systematically. *Haemostasis* 23 (suppl. 1): 144–149

Hamada J, Cavanagh PG and Lotan R (1992) Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. *Invasion Metastasis* 14: 395–408

Jakobson AM and Hahnenberger R (1991) Antiangiogenic effect of heparin and other sulphated glycosaminoglycans in the chick embryo chorioallantoic membrane. *Pharmacol Toxicol* 69: 122–126

Kessler DA, Langer RS, Pless NA and Folkman J (1976) Mast cells and tumor metastasis. *Invasion Metastasis* 14: 395–408

Klein B (1995) Cytokine, cytokine receptors, transduction signals and oncogenes in human multiple myeloma. *Semin Hematol* 32: 4–19

Kop SK, Van Loveren H, Rosenberg RW, Ptak W and Askenase PW (1984) Mast cell activation and vascular alterations in immediate hypersensitivity-like reactions induced by a T-cell-derived antigen-binding factor. *Lab Invest* 50: 421–434

Kresse H, Messina M and Kiewra A (1990) Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. *Proc Natl Acad Sci USA* 87: 4068–4072

Lichtenstein A, Berenson J, Norman D, Chang M-P and Carlile A (1989) Bone marrow angiogenesis and progression in multiple myeloma. *Br J Haematol* 71: 503–508

Lichtermann A, Berenson J, Norman D, Chang M-P and Carlile A (1989) Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. *Blood* 74: 1266–1273

Meininger EJ and Zetter BR (1992) Mast cells and angiogenesis. *Semin Cancer Biol* 3: 73–79

Motro B, Bini A, Sachs L and Keskeh E (1990) Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis, *Proc Natl Acad Sci USA* 87: 4068–4072

Nakamura M, Merchav S, Carter A, Ernst TJ, Demetri GD, Furukawa Y, Anderson K, Freedman AS and Griffith JD (1989) Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. *J Immunol* 143: 3543–3547

Norrby K (1993) Heparin and angiogenesis: a low molecular weight fraction inhibits and a high-molecular weight fraction stimulates angiogenesis systematically. *Blood* 78: 2488–2493

Norrby K (1996) Interleukin-6 and *de novo* mammalian angiogenesis. *Cell Proliferation* 29: 315–323

Norrby K and Wholey D (1993) Role of mast cells in mitogenesis and angiogenesis in normal tissues and tumour tissues. *Adv Biosci* 89: 71–136

Norrby K (1996) Interleukin-6 and *de novo* mammalian angiogenesis. *Cell Proliferation* 29: 315–323

Ribatti D, Roncalli L, Nico B and Bertossi M (1987) Effects of exogenous heparin on the vascularity of the choroidaioaenine membrane. *Acta Anat* 130: 257–263

Ribatti D, Contino R and Tursi A (1988) Do mast cells intervene in the vasoproliferative processes of the rheumatoid synovitis? *Submicrosc Cytol Pathol* 20: 635–637

Ribatti D, Nico B, Vaca A, Marzullo A, Calvi N, Roncalli L and Dammacco F (1998) Do mast cells help to induce angiogenesis in B-cell non-Hodgkin lymphomas? *Br J Cancer* 77: 1900–1906

Roberts AR, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine BJ, Liotta LA, Falanga V, Kehr JH and Fauci AS (1986) Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis *in vivo* and stimulation of collagen formation *in vitro*. *Proc Natl Acad Sci USA* 83: 4167–4171

Schwab G, Siegall CB, Aarden LA, Neckers LM and Nordan RP (1991) Characterization of an interleukin-6 mediated autocrine growth loop in the human multiple myeloma cell line, U266. *Blood* 77: 587

Sorbo J, Jakobson A and Norrby K (1994) Mast cell histamine is angiogenic through receptors for histamine 1 and histamine 2. *Int J Exp Pathol* 75: 43–50

Starkey JR, Crowle PK and Taubenberger S (1988) Mast cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. *Int J Cancer* 42: 48–52

Taylor S and Folkman J (1982) Protamine is an inhibitor of angiogenesis. *Nature* 297: 307–312

Thorton SC, Mueller SM and Levine EM (1983) Human endothelial cells: use of heparin in cloning and long term cultivation. *Science* 222: 623–625

Vaccà A, Ribatti D, Roncalli L, Ranieri G, Serio G, Silvestris F and Dammarco F (1994) Bone marrow angiogenesis and progression in multiple myeloma. *Br J Haematol* 87: 503–508

Vaccà A, Moretti S, Ribatti D, Pellegrino A, Pimpinelini N, Bianchi B, Bonifazi E, Ria R, Serio G and Dammarco F (1997) Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. *Eur J Cancer* 33: 1685–1692

Wilks JM, Scott PS, Urla LK and Cocuzza JM (1991) Inhibition of angiogenesis with combination treatments of angiotas tic steroids and suramin. *Int J Radiat Biol* 60: 73–77